Inventor · disambiguated record
Joël Jean-Mairet
Also filed as: JEAN-MAIRET JOEL · JEAN-MAIRET JOËL
18 granted patents·1 pending application·2,107 citations·filing 1999–2021
95Inventor score
Top patents by PatentIndex Score
19 records- 0198US8021856B2Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicityROCHE GLYCART AG·Filed 2005·Granted Sep 20, 2011·51 cites·19 claims
- 0298US6602684B1Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicityGLYCART BIOTECHNOLOGY AG·Filed 1999·Granted Aug 5, 2003·1.8k cites·10 claims
- 0397US7517670B2Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicityGLYCART BIOTECHNOLOGY AG·Filed 2003·Granted Apr 14, 2009·83 cites·67 claims
- 0496US11041213B2Method for the diagnosis, prognosis and treatment of prostate cancer metastasisINBIOMOTION SL·Filed 2018·Granted Jun 22, 2021·9 cites·11 claims
- 0596US11041861B2Method for the diagnosis, prognosis and treatment of prostate cancer metastasisINBIOMOTION SL·Filed 2018·Granted Jun 22, 2021·9 cites·22 claims
- 0696US10119171B2Method for the diagnosis, prognosis and treatment of prostate cancer metastasisINBIOMOTION SL·Filed 2016·Granted Nov 6, 2018·14 cites·20 claims
- 0795US8629248B2Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicityUMANA PABLO·Filed 2010·Granted Jan 14, 2014·21 cites·15 claims
- 0895US8623644B2Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicityUMANA PABLO·Filed 2010·Granted Jan 7, 2014·22 cites·45 claims
- 0995US7906329B2Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicityGLYCART BIOTECHNOLOGY AG·Filed 2003·Granted Mar 15, 2011·50 cites·43 claims
- 1091US10114022B2Method for the diagnosis, prognosis and treatment of prostate cancer metastasisINBIOMOTION SL·Filed 2013·Granted Oct 30, 2018·14 cites·31 claims
- 1188US9321843B2Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicityROCHE GLYCART AG·Filed 2015·Granted Apr 26, 2016·3 cites·43 claims
- 1287US8999324B2Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicityUMAÑA PABLO·Filed 2011·Granted Apr 7, 2015·4 cites·39 claims
- 1385US9068005B2Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicityUMAÑA PABLO·Filed 2009·Granted Jun 30, 2015·4 cites·18 claims
- 1484US9139654B2Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicityUMAÑA PABLO·Filed 2010·Granted Sep 22, 2015·4 cites·29 claims
- 1576US11892453B2Method for the diagnosis, prognosis and treatment of prostate cancer metastasisINBIOMOTION SL·Filed 2021·Granted Feb 6, 2024·0 cites·24 claims
- 1675US11840740B2Method for the diagnosis, prognosis and treatment of prostate cancer metastasisINBIOMOTION SL·Filed 2021·Granted Dec 12, 2023·0 cites·23 claims
- 1763US9631023B2Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicityROCHE GLYCART AG·Filed 2016·Granted Apr 25, 2017·0 cites·30 claims
- 1862US2003175884A1Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicityFiled 2002·Application pending·0 cites
- 1961US9718885B2Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicityROCHE GLYCART AG·Filed 2015·Granted Aug 1, 2017·0 cites·24 claims
Join the waitlist — get patent alerts
Get an alert when Joël Jean-Mairet files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →